Table 3.

Effect of chronic treatment with studied compounds on locomotor activity in mice

Treatment	Dose of the studied compound (mg/kg)	Number of crossings ± S.E.M
Saline + vehicle	–	366.0 ± 59.3
Saline + corticosterone	–	343.4 ± 27.3
HBK-14 + corticosterone	1.25	406.3 ± 64.2
HBK-14 + corticosterone	2.5	400.8 ± 55.8
Fluoxetine + corticosterone	10	423.3 ± 47.3
Saline + vehicle	–	436.9 ± 71.7
Saline + corticosterone	–	394.5 ± 67.1
HBK-15 + corticosterone	0.625	466.1 ± 84.8
HBK-15 + corticosterone	1.25	478.9 ± 78.8
Fluoxetine + corticosterone	10	510.3 ± 54.0

Corticosterone (20 mg/kg) was injected subcutaneously (s.c.) for 3 weeks at random times during the light phase. Additionally, 30 min before, corticosterone administration mice were intraperitoneally (i.p.) injected with HBK-14 (1.25 or 2.5 mg/kg), HBK-15 (0.625 or 1.25 mg/kg), fluoxetine (10 mg/kg), or 0.9% NaCl (saline). Control groups received saline (i.p.) and 30 min later saline containing 0.1% dimethyl sulfoxide (DMSO) and 0.1% Tween-80 (vehicle, s.c.). Statistical analysis: one-way ANOVA (Newman–Keuls post hoc); n = 8 mice per group